Compare AbbVie Inc (ABBV) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Chipotle Mexican Grill, Inc. — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Chipotle Mexican Grill, Inc. trades at $33.33 (market cap $44.06B). The key difference: AbbVie Inc is far larger — about 10.2× Chipotle Mexican Grill, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | CMG | |
|---|---|---|
Market Cap | $449.91B | $44.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $56.41 |
52-Week Low | $184.85 | $28.17 |
Enterprise Value | $513.38B | $48.44B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Chipotle Mexican Grill (CMG) trades at $34.35, down 2.91% over 24 hours, with a bullish technical signal from moving averages and strong fundamentals including a 49.23% ROE and consistent earnings beats. Revenue grew to $11.93B in 2025, though net cash flow turned negative due to aggressive financing activities. Recent news highlights operational excellence and menu innovation as growth drivers amid competitive pressures.
Outlook remains positive with a $40.46 analyst consensus price target (70% buy ratings), but risks include cost inflation and softer comps. The stock offers upside from execution of expansion plans, yet investors face headwinds from consumer sentiment and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
